BENEPHARMA
ActiveSummary
BENEPHARMA has been active since 2017 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €505k and a net result of €135k. Equity is growing by ~31.2% per year across the filed fiscal years. Its solvency ranks better than 71% of 9623 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.9% (low).
Checked score
Score 2024
78
/ 100
Excellent
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2023
Profitability88▲+8
Solvency83▲+8
Growth78=
Track record100
Bankruptcy probability, 12 months
0.9%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €35k at 30 days acceptable
Liquidity ample (current ratio 2.9 against 1.97 in 2023; short-term debt: 17% and cash: 19.2% of total assets), and 42.4% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Two signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 24-06-2025, 37 days ahead of the deadline.
NBB · 7 filingsDeviation from the deadline
2025
not confirmed
2024
37 d early
2023
20 d late
2022
21 d late
2021
17 d early
2020
5 d late
2019
32 d late
← before the deadline
after the deadline →
Checked, nothing found (1)
Financials · fiscal year 2024, abbreviated schema
Equity
€505k▲ 28.0%
2023 · €394k
2018: €40k
2019: €88k
2020: €164k
2021: €247k
2022: €324k
2023: €394k
2018 → 2024
Total assets
€876k▲ 11.5%
2023 · €786k
2018: €775k
2019: €864k
2020: €730k
2021: €708k
2022: €726k
2023: €786k
2018 → 2024
Net result
€135k▲ 92.9%
2023 · €70k
2018: €27k
2019: €48k
2020: €76k
2021: €84k
2022: €77k
2023: €70k
2018 → 2024
Working capital
€282k▲ 106%
2023 · €137k
2018: €-196k
2019: €-103k
2020: €32k
2021: €117k
2022: €159k
2023: €137k
2018 → 2024
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20202021202220232024Trend
Equity€164k-€247k▲ 51.0%€324k▲ 31.2%€394k▲ 21.7%€505k▲ 28.0%
Operating result€66k-€91k▲ 38.0%€112k▲ 23.6%€106k▼ 5.8%€202k▲ 90.8%
Net result€76k-€84k▲ 10.0%€77k▼ 7.8%€70k▼ 8.8%€135k▲ 92.9%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2024; 2024 is 91% above 2023 and is the highest result in the available series.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €876k
Fixed assets
€445k ▼ 12.3%
Current assets
€431k ▲ 54.9%
Equity and liabilities €876k
Equity
€505k ▲ 28.0%
Debt
€371k ▼ 5.2%
Debt's share of the balance-sheet total falls from 49.8% to 42.4%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€275k▲
2023 · €178k
Cash flow
€208k▲
2023 · €142k
Current ratio
2.90▲
2023 · 1.97
Quick ratio
1.76▲
2023 · 0.80
Debt to equity
0.74▼
2023 · 0.99
ROE
26.8%▲
2023 · 17.8%
ROA
15.5%▲
2023 · 8.9%
Interest coverage
29.73▲
2023 · 21.33
Debt ≤ 1 year
€149k▲
2023 · €141k
Debt > 1 year
€220k▼
2023 · €248k
Income taxes
€58k▲
2023 · €28k
Staff costs
€150k▼
2023 · €172k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2024 against 2023 · 57 lines
Balance sheet
Code20232024
Assets
Total assets20/58€786k€876k▲
Fixed assets21/28€508k€445k▼
Intangible fixed assets21€60k€45k▼
Tangible fixed assets22/27€390k€345k▼
Land and buildings22€219k€197k▼
Plant, machinery and equipment23€79k€69k▼
Furniture and vehicles24€92k€78k▼
Financial fixed assets28€58k€55k▼
Current assets29/58€278k€431k▲
Stocks and contracts in progress3€165k€170k▲
Stocks30/36€165k€170k▲
Amounts receivable within one year40/41€67k€90k▲
Trade receivables40€67k€90k▲
Other amounts receivable41€4€4▲
Cash at bank and in hand54/58€40k€168k▲
Deferred charges and accrued income490/1€6k€3k▼
Equity and liabilities
Total equity and liabilities10/49€786k€876k▲
Equity10/15€394k€505k▲
Contributions10/11€12k€12k=
Reserves13€382k€492k▲
Non-distributable reserves130/1€2k€2k=
Reserves not available under the articles1311€2k€2k=
Distributable reserves133€380k€491k▲
Profit (loss) carried forward14-€0
Amounts payable17/49€392k€371k▼
Amounts payable after more than one year17€248k€220k▼
Financial debts170/4€248k€220k▼
Amounts payable within one year42/48€141k€149k▲
Current portion of amounts payable after more than one year42€27k€28k▲
Trade debts44€48k€47k▼
Suppliers440/4€48k€47k▼
Taxes, remuneration and social security45€30k€26k▼
Taxes450/3€4k€4k▲
Remuneration and social security454/9€25k€21k▼
Other amounts payable47/48€37k€49k▲
Accrued charges and deferred income492/3€3k€3k▲
Income statement
Code20232024
Non-recurring operating income76A€0-
Remuneration, social security and pensions62€172k€150k▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€72k€73k▲
Other operating charges640/8€670€972▲
Gross operating margin9900€351k€426k▲
Operating profit (loss)9901€106k€202k▲
Financial income75/76B€387€720▲
Recurring financial income75€387€720▲
Financial charges65/66B€8k€9k▲
Recurring financial charges65€8k€9k▲
Profit (loss) for the period before taxes9903€98k€194k▲
Income taxes67/77€28k€58k▲
Profit (loss) for the period9904€70k€135k▲
Profit (loss) for the period to be appropriated9905€70k€135k▲
Appropriation of the result
Profit (loss) to be appropriated9906€70k€135k▲
Transfer from equity791/2-€25k
Transfer to equity691/2€70k€135k▲
To other reserves6921€70k€135k▲
Profit to be distributed694/7-€25k
Return on contributions (dividend)694-€25k
Social balance
Average headcount (FTE)90872.62.7▲
The notes to these accounts (17 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
2025
24-06
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-12
Financial
Highest result since 2018net €135k ▲92.9%
Operating result €202k, net result €135k, both a record.
31-12
Financial
Equity above €500kEq €505k ▲28%
7 profitable years in a row build equity to €505k.
20-08
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema · 20 days late
2023
21-08
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema · 21 days late
2022
14-07
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
31-12
Financial
Equity above €200kEq €247k ▲51%
4 profitable years in a row build equity to €247k.
05-08
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema · 5 days late
2020
31-12
Financial
Equity above €150kEq €164k ▲86.5%
3 profitable years in a row build equity to €164k.
01-09
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema · 32 days late
2019
23-08
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema · 23 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Overijse · 1 establishment unit since 2017
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Stationsstraat 363090 OverijseGround area
341 m²
Building footprint
189 m²
Volume, LiDAR
1,173 m³
Parcel 23546L0096/00X004, Flanders · tallest building 13.7 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
BENEPHARMA
since 20172.270.837.504
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 23546L0096/00X004 | Flanders | 341 m² | 1 · 189 m² | 13.7 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Recognitions · licences · registrations
Food safety, FASFC
1 siteOverijse2.270.837.504
Similar companies · same sector, comparable size
APOTHEEK VANACHTER
BE 0425.070.133
Puurs-Sint-Amands · Eq €504,693
APOTHEEK GLIBERT-LOX
BE 0829.917.251
Ronse · Eq €504,639
Anglopharma
BE 0406.061.794
De Panne · Eq €504,483
PHARMACIE GUILMIN - LAMBEAU
BE 0430.195.691
Wavre · Eq €504,301
APOTHEEK BAETENS
BE 0429.339.123
Evergem · Eq €504,092
Of 5,220 companies in sector 47730 we hold annual accounts for 3,861. 3,357 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company (pre-2019)
Founded15-12-2017
Fiscal year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
64210Activities of holding companies
Sources
Crossroads Bank for EnterprisesNational Bank · 7 filingsAddress and cadastre registers
Scores and ratios are computed by Checked and are not a credit decision.